178 related articles for article (PubMed ID: 21735096)
61. CK2 phosphorylation of C/EBPδ regulates its transcription factor activity.
Schwind L; Zimmer AD; Götz C; Montenarh M
Int J Biochem Cell Biol; 2015 Apr; 61():81-9. PubMed ID: 25680545
[TBL] [Abstract][Full Text] [Related]
62. Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.
Gratz A; Kuckländer U; Bollig R; Götz C; Jose J
Mol Cell Biochem; 2011 Oct; 356(1-2):83-90. PubMed ID: 21750981
[TBL] [Abstract][Full Text] [Related]
63. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.
Prudent R; López-Ramos M; Moucadel V; Barette C; Grierson D; Mouawad L; Florent JC; Lafanechère L; Schmidt F; Cochet C
Biochim Biophys Acta; 2008 Dec; 1780(12):1412-20. PubMed ID: 18674590
[TBL] [Abstract][Full Text] [Related]
64. CK2 is responsible for phosphorylation of human La protein serine-366 and can modulate rpL37 5'-terminal oligopyrimidine mRNA metabolism.
Schwartz EI; Intine RV; Maraia RJ
Mol Cell Biol; 2004 Nov; 24(21):9580-91. PubMed ID: 15485924
[TBL] [Abstract][Full Text] [Related]
65. Salicylic acid-inducible Arabidopsis CK2-like activity phosphorylates TGA2.
Kang HG; Klessig DF
Plant Mol Biol; 2005 Mar; 57(4):541-57. PubMed ID: 15821979
[TBL] [Abstract][Full Text] [Related]
66. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
67. Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.
Guerra B; Hochscherf J; Jensen NB; Issinger OG
Mol Cell Biochem; 2015 Aug; 406(1-2):151-61. PubMed ID: 25963666
[TBL] [Abstract][Full Text] [Related]
68. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
69. The dark side of protein kinase CK2 inhibition.
Cozza G; Meggio F; Moro S
Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
[TBL] [Abstract][Full Text] [Related]
70. Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis.
Wang J; Feng C; He Y; Ding W; Sheng J; Arshad M; Zhang X; Li P
Oncotarget; 2015 Sep; 6(29):27700-13. PubMed ID: 26172393
[TBL] [Abstract][Full Text] [Related]
71. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
72. Involvement of the protein kinase CK2 in the regulation of mammalian circadian rhythms.
Tsuchiya Y; Akashi M; Matsuda M; Goto K; Miyata Y; Node K; Nishida E
Sci Signal; 2009 Jun; 2(73):ra26. PubMed ID: 19491384
[TBL] [Abstract][Full Text] [Related]
73. Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
Golub AG; Bdzhola VG; Ostrynska OV; Kyshenia IV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Yarmoluk SM
Bioorg Med Chem; 2013 Nov; 21(21):6681-9. PubMed ID: 24011954
[TBL] [Abstract][Full Text] [Related]
74. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
75. Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells.
Ahmad KA; Wang G; Ahmed K
Mol Cancer Res; 2006 May; 4(5):331-8. PubMed ID: 16687488
[TBL] [Abstract][Full Text] [Related]
76. Specific interaction between casein kinase 2 and the nucleolar protein Nopp140.
Li D; Meier UT; Dobrowolska G; Krebs EG
J Biol Chem; 1997 Feb; 272(6):3773-9. PubMed ID: 9013635
[TBL] [Abstract][Full Text] [Related]
77. Casein kinase 2-mediated phosphorylation of Brahma-related gene 1 controls myoblast proliferation and contributes to SWI/SNF complex composition.
Padilla-Benavides T; Nasipak BT; Paskavitz AL; Haokip DT; Schnabl JM; Nickerson JA; Imbalzano AN
J Biol Chem; 2017 Nov; 292(45):18592-18607. PubMed ID: 28939766
[TBL] [Abstract][Full Text] [Related]
78. Features and potentials of ATP-site directed CK2 inhibitors.
Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
[TBL] [Abstract][Full Text] [Related]
79. Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
Sekiguchi Y; Nakaniwa T; Kinoshita T; Nakanishi I; Kitaura K; Hirasawa A; Tsujimoto G; Tada T
Bioorg Med Chem Lett; 2009 Jun; 19(11):2920-3. PubMed ID: 19414254
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
